Outcomes of First-Line PARP Inhibitor Therapy in Ovarian Cancer: A Multicenter Retrospective Analysis.

J Clin Med · 2026 · PMC12942131 · PMID 41753346

Europe PMC DOI

hedged sentence

0.0880

closest p · 1.8× alpha

0.0880

boldest claim

The sentences

did not reach statistical significancep = 0.088so close (0.05 < p ≤ 0.1)

22.5 months), although this difference did not reach statistical significance ( p = 0.088).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.